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Objective: To determine whether changing the transfer set on completion of antibiotic treatment for peritonitis
affects the rate of relapsing peritonitis.
Methods: This randomized prospective study conducted in a renal unit in Hong Kong recruited all continuous
ambulatory peritoneal dialysis (CAPD) patients who developed peritonitis and were successfully treated between
August 2001 and October 2002. Exclusion criteria were tuberculosis or fungal peritonitis, relapsing peritonitis,
peritonitis coexisting with exit-site or tunnel infection, and antibiotics due to infection of other origin. Patients
were randomized to either transfer set change (Group I) or no transfer set change (Group II) on completion of
antibiotic treatment.
Results: A total of 38 patients were recruited in Group I and 33 patients in Group II. The two groups were
comparable for demographic data, duration of CAPD, and culture results. There were two episodes of relapsing
peritonitis in both groups. There was no significant difference in relapsing peritonitis rates between patients
who had the transfer set changed and those who did not have the transfer set changed.
Conclusions: Changing the transfer set on completion of antibiotic treatment for peritonitis does not reduce
the relapsing peritonitis rate. This practice of transfer set change after antibiotic treatment may not be necessary
to prevent relapsing peritonitis. [Hong Kong J Nephrol 2004;6(2):87–91]
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INTRODUCTION
Continuous ambulatory peritoneal dialysis (CAPD) is
one form of treatment for patients with end-stage renal
disease. The CAPD population has been increasing
worldwide, with a rapid growth in most European
countries [1], while in Asia, there are almost 30,000
patients maintained on peritoneal dialysis [2]. In
Hong Kong, it is the main form of dialysis therapy,
constituting 82.5% of the dialysis population, with
3,135 patients in 2004 [3]. Once a patient is started on
peritoneal dialysis, one of the most frequent compli-
cations is peritonitis [4]. Although peritonitis rates
vary from place to place, there is approximately one
episode of peritonitis in every 24 patient-treatment-
months [5]. Peritonitis remains a major complication
of peritoneal dialysis, accounting for much of the
morbidity associated with peritoneal dialysis [6]. It
accounts for catheter removal and technique failure
resulting in patient dropout from peritoneal dialysis
therapy and is one of the leading causes of hospi-
talization [7,8]. Peritonitis is also a cause of death
among CAPD patients [9,10]. In particular, relapsing
peritonitis is a serious problem leading to catheter
removal and replacement; it also results in catheter loss
and the requirement for alternate renal replacement
therapy [11,12].
Considerable effort has been made to reduce the
occurrence of peritonitis in the CAPD population.
Changing the transfer set after antibiotic treatment for
peritonitis has been used to prevent the relapse of
peritonitis. This practice, although not evidence-based,
has been carried out in some dialysis centers, but is not
universally adopted as standard practice. This study
was conducted to evaluate the effect of changing the
transfer set on relapsing peritonitis.
METHODS
This randomized prospective study was conducted in
patients who had peritonitis successfully treated with
antibiotics. It was approved by the ethical committee
of the hospital. Informed consent was obtained from
each patient after explanation so that patients had a full
understanding of the study prior to participation.
All CAPD patients who developed bacterial peri-
tonitis and were successfully treated with antibiotics
between August 2001 and October 2002 were recruited
into the study. Peritonitis was treated with empirical
antibiotics for 14 days after culture results became
available and for 21 days if culture results showed
Staphylococcus aureus or Pseudomonas aeruginosa.
Exclusion criteria for the study included tuberculosis
or fungal peritonitis, relapsing peritonitis, peritonitis
with exit-site infection or tunnel infection, and antibiotic
due to infection of other origins.
Patients were randomized into one of two groups
by drawing envelopes on the last day of antibiotic
treatment. Patients in Group I had their transfer sets
changed within 24 hours of completion of antibiotic
treatment, while patients in Group II had their transfer
sets unchanged. All patients were monitored for signs
and symptoms of peritonitis in the following 28 days,
to detect relapsing peritonitis.
Peritonitis was defined as the presence of at least
two of the following: signs and symptoms of peritoneal
inflammation including abdominal pain with or with-
out fever; cloudy effluent with a white blood cell (WBC)
count of more than 100/mL and more than 50% neu-
trophils; and culture results showing bacteria in the
effluent [13]. Successful treatment of peritonitis was
confirmed by no signs and symptoms of peritonitis and
a negative culture on completion of treatment.
Relapsing peritonitis was defined as another episode
of peritonitis caused by the same genus/species of or-
ganism that caused the immediately preceding episode,
occurring within 4 weeks of completion of the antibiotic
course [5]. If the culture result was negative, the deci-
sion of whether it was relapsing peritonitis was made
according to the medical judgment of the nephrologist.
The number of episodes of relapse was monitored.
The difference between the two groups in demographic
and clinical parameters were analyzed using t test, Chi-
squared test, and Fisher’s exact test, and a p value of
less than 0.05 was considered statistically significant.
RESULTS
A total of 73 patients were recruited into the study.
Two patients were excluded from analyses due to in-
complete resolution of peritonitis on completion of
treatment, as revealed by belated results showing
positive culture from the effluent taken on the last day
of antibiotic treatment. Data for the remaining 71 pa-
tients were analyzed. There were 38 patients in Group
I and 33 in Group II. Demographic data are shown in
Table 1. There were no statistically significant differ-
ences between the two groups in gender distribution,
age, time on CAPD, and the presence of diabetes.
Culture results were categorized into four groups:
Gram-positive, Gram-negative, mixed growth, and
negative. There was no statistically significant differ-
ence between the groups in culture results (Table 2).
Causative microorganisms are shown in Table 3.
There were four cases of relapsing peritonitis, two
in each group. All relapses occurred within 2 weeks
after completion of treatment of the previous episode
of peritonitis (Table 4).
Two patients developed a second episode of peri-
tonitis within 4 weeks after completion of antibiotic
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treatment. However, these episodes were caused by
microorganisms that were different from those caus-
ing the preceding episode. The microorganisms that
caused the initial and consecutive peritonitis were
Streptococcus group D and _-hemolytic Streptococcus
in one patient, and coagulase-negative Staphylococcus
and Peptostreptococcus in the second patient. These
two patients were not classified as having relapsing
peritonitis due to the different causative microorgan-
isms. Both of these patients had had their transfer sets
changed.
DISCUSSION
Peritonitis is a major complication of peritoneal dialy-
sis therapy. To prevent the recurrence of peritonitis,
strategies should be targeted at elimination of the
original causes according to the individual’s situation.
It is essential to make a correct diagnosis of whether
the consecutive peritonitis is a relapse or not. Labora-
tory test results on the strains of causative organisms
of the initial and consecutive episodes are important
in making a correct diagnosis. If the consecutive epi-
sode of peritonitis is caused by a different strain of caus-
ative microorganism, it is not classified as relapsing
peritonitis.
Recurrence of peritonitis is the reappearance of
symptoms of infection [14], which could be due to the
same microorganism or a different microorganism,
classified as relapse and re-infection, respectively [15].
It is important to differentiate between the two
conditions, not only because it affects the management
of CAPD patients, but also because it helps to explain
the mechanism of infection, making appropriate pre-
ventive measures possible [15].
It has been reported that two-thirds of all recurrent
episodes of peritonitis are relapses, while one-third
are due to re-infection [16]. In our study, there were
two cases of re-infection, accounting for one-third of
the recurrent peritonitis. The results were similar to
reported data [16]. Both cases were in the group of
patients who had had their transfer sets changed. All
causative microorganisms of the initial and consecutive
episodes of peritonitis were Gram-positive organisms
found on human skin. It is assumed that these episodes
were caused by intramural infection from external
sources, which may be attributed to contamination of
the system due to poor technique during bag exchange
procedures. Preventive measures for recurrence of
peritonitis for these patients should therefore be tar-
geted at maintaining a high standard of hygiene and
compliance with proper technique during bag exchange
procedures.
Relapsing peritonitis is a serious problem. It has
a graver prognosis with a lower cure rate and higher
removal rate than re-infection [15]. Relapsing peri-
tonitis often leads to removal and replacement of peri-
Table 1. Demographic data
Group I (n = 38) Group II (n = 33) p
Gender (M:F) 21:17 16:17 NS
Age (yr) 65.8 ( 9.1 62.2 ( 14.1 NS
Duration on CAPD (mo) 25.6 ( 21 23 ( 17 NS
Presence of DM 16 (42%) 10 (32%) NS
M = male; F = female; CAPD = continuous ambulatory peritoneal dialysis; DM = diabetes mellitus.
Table 2. Peritonitis culture results
Group I Group II p (n = 38) (n = 33)
Gram-positive organisms 16 16 NS
Gram-negative organisms 14 18 NS
Mixed growth 13 13 NS
Culture negative 15 16 NS
Table 3. Causative microorganisms
Group I Group II
Gram-positive
   Staphylococcus aureus 5 4
   Other Staphylococcus species 6 5
   Streptococcus species 6 8
   Bacillus species 1 2
Other Gram-positive species 4 1
Gram-negative
   Klebsiella species 0 3
   Escherichia coli 8 4
   Pseudomonas species 4 1
   Xanthomonas species 0 1
Other Gram-negative species 3 0
Table 4. Results of relapsing peritonitis
Group I Group II
(n = 38) (n = 33)
Relapse episode 2 2
Staphylococcus aureus 1 1
Coagulase-negative Staphylococcus 0 1
Culture negative 1 0
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toneal dialysis catheters and/or alternative renal re-
placement therapy [12]. There are different causes
of relapsing peritonitis: inadequate treatment of the
prior peritonitis, the presence of an endogenous focus
from which seeding occurs, exit-site or tunnel infection,
or bacteria harbored in a catheter biofilm [6,14,17].
Biofilm is generated when free-floating bacteria in
an aqueous environment contact and adhere to a for-
eign surface such as a catheter. After attachment, the
bacterium proliferates into bacterial microcolonies
and biofilm. Biofilm is a coating of exopolysaccharide
that envelopes the bacterial community of microcolo-
nies, and which enables the microcolonies within it to
replicate and form larger biofilm populations. It protects
the bacteria from antibiotics and allows them to acquire
resistance to antibiotics over time [18,19].
Biofilm is easily generated on the peritoneal dialysis
catheter in the peritoneal dialysis environment with its
glucose-based dialysis solution, and it is inevitable over
time in CAPD patients, regardless of their peritonitis
history [18–20]. Biofilm is also generated from skin
bacteria in the exit site that colonize catheter surfaces
and spread along the outside of the catheter and transfer
across the peritoneum via the catheter cuff. It forms on
the surface of biomaterials, including silastic materials
and polyurethane, and tends to persist on the catheter
surface [19,21,22].
Bacteria colonized within a biofilm may act as a
source of peritonitis, and it is believed that the biofilm
may lead to relapsing peritonitis [19,23]. Research data
also suggest that the source of repetitive infections may
be within the catheter itself, and only when the catheter
is removed and replaced does the organism clear [16].
However, it has been argued that the presence of
biofilm on catheters alone does not necessarily lead to
peritonitis. A weakened or failed host defense mech-
anism may lead to dissemination of bacteria from
a biofilm, resulting in peritonitis [14,19]. Host defense
factors may be the most important determinants of
whether dissemination of bacteria from biofilm reser-
voir populations is a direct cause of peritonitis [19].
Host defense is the ability of individual subjects to
resist infection. It is believed that patients with diabetes
and elderly patients have a decreased host defense and
are more susceptible to infection. Host defense has been
reported as one factor responsible for some patients on
CAPD suffering from repeated peritonitis while others
remain relatively free of peritonitis [24]. The factors of
age and the presence of diabetes were analyzed in this
study to exclude host defense from affecting the results.
There were no significant differences between the two
groups of patients in age and the presence of diabetes,
indicating that the two groups were comparable with
regard to host defense.
It has been reported that S. aureus and S. epidermidis
are the most common organisms involved in relapsing
peritonitis. Patients with either of these organisms in
their first episode of peritonitis are more likely to have
a relapse [16]. Bacterial growth from cultures of scrap-
ings from biofilm on peritoneal catheters removed from
patients with and without peritoneal dialysis show that
S. aureus and S. epidermidis are the most predominant
bacteria growing in catheter biofilms [19].
Of the four cases of relapsing peritonitis in our study,
two were due to S. aureus and one was due to coagulase-
negative Staphylococcus. S. epidermidis is the most
common coagulase-negative staphylococcus identified
in CAPD peritonitis [14]. It is likely that the relapses
were related to biofilm bacteria, given the absence of
exit-site and tunnel infection. The last case of relapsing
peritonitis in our study was culture negative on both
the initial and consecutive episodes, which is reported-
ly common in relapsing peritonitis [13].
The problem of relapsing peritonitis has led to dif-
ferent suggestions for therapy. Elimination of biofilm
bacteria from the catheter itself can be achieved by
removal and replacement of the peritoneal cathe-
ter. However, this is comparatively expensive and is
unpleasant for the patient. Intralumen fibrinolytic
enzymes including streptokinase and urokinase have
also been used. These act on fibrin, resulting in fi-
brinolysis that releases the microorganisms trapped
in the fibrin within the catheter. The microorganisms
freed from the protective shield become vulnerable to
antibiotic treatment [12,13]. This intervention is used
in an attempt to achieve complete resolution of the
peritonitis and prevent relapse of the infection. How-
ever, the effect of using streptokinase and urokinase is
still not clear. Some studies have demonstrated the
effectiveness of the therapy while others have not [25–
27].
Another strategy to reduce biofilm is to change the
transfer set. The transfer set is the part of the basic
CAPD system that attaches to the peritoneal dialysis
catheter. During bag exchange, a bag of dialysate with
Y-shaped tubing and an empty bag are connected to
the transfer set to drain and re-infuse the dialysate. The
transfer set is usually changed every 6 months according
to the recommendation of the manufacturer. In some
dialysis centers, it is also changed after treatment of
peritonitis. The aim is to remove a transfer set that may
have biofilm on it. It is based on the rationale that the
development of intraluminal biofilm may favor the
adherence of microorganisms to the transfer set and
re-infect the patient [28]. However, there is no research
evidence on the benefit of changing the transfer set after
peritonitis treatment.
Changing of the transfer set after peritonitis enables
the biofilm on the transfer set to be removed, while
biofilm on the peritoneal dialysis catheter remains. The
practice can therefore reduce part of the biofilm in the
CAPD system. Whether reduction of biofilm in the
Hong Kong J Nephrol • October 2004 • Vol 6 • No 2 91
Effect of transfer set change on relapse of bacterial peritonitis
CAPD system reduces the rate of relapsing peritonitis
is not known. In our study, there was no significant
difference in the rate of relapsing peritonitis between
patients who had their transfer sets changed and those
who did not. Changing the transfer set did not reduce
the incidence of relapsing peritonitis.
CONCLUSIONS
The occurrence of relapsing peritonitis has led to the
practice of changing the transfer set on completion of
antibiotic treatment for peritonitis. This study was
undertaken to determine whether changing the transfer
set affected the incidence of relapsing peritonitis. The
rate of relapsing peritonitis in patients with their transfer
sets changed was not significantly different from that
in patients with their transfer sets unchanged. Changing
the transfer set on completion of antibiotic treatment
for peritonitis did not reduce the relapsing peritonitis
rate. The practice may be unnecessary for the preven-
tion of relapsing peritonitis.
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